These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 17116235)

  • 1. Monoclonal antibodies that target pathological assemblies of Abeta.
    Lambert MP; Velasco PT; Chang L; Viola KL; Fernandez S; Lacor PN; Khuon D; Gong Y; Bigio EH; Shaw P; De Felice FG; Krafft GA; Klein WL
    J Neurochem; 2007 Jan; 100(1):23-35. PubMed ID: 17116235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons.
    Shughrue PJ; Acton PJ; Breese RS; Zhao WQ; Chen-Dodson E; Hepler RW; Wolfe AL; Matthews M; Heidecker GJ; Joyce JG; Villarreal SA; Kinney GG
    Neurobiol Aging; 2010 Feb; 31(2):189-202. PubMed ID: 18486276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal.
    Pitt J; Roth W; Lacor P; Smith AB; Blankenship M; Velasco P; De Felice F; Breslin P; Klein WL
    Toxicol Appl Pharmacol; 2009 Oct; 240(2):189-97. PubMed ID: 19631677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins.
    Lambert MP; Velasco PT; Viola KL; Klein WL
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):65-81. PubMed ID: 19275637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease.
    Li S; Jin M; Liu L; Dang Y; Ostaszewski BL; Selkoe DJ
    Acta Neuropathol Commun; 2018 Nov; 6(1):121. PubMed ID: 30409172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aβ oligomers-induced toxicity is attenuated in cells cultured with NbActiv4™ medium.
    Zhou Y; Klein WL
    Neurotox Res; 2012 Nov; 22(4):335-44. PubMed ID: 22441766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.
    Izzo NJ; Xu J; Zeng C; Kirk MJ; Mozzoni K; Silky C; Rehak C; Yurko R; Look G; Rishton G; Safferstein H; Cruchaga C; Goate A; Cahill MA; Arancio O; Mach RH; Craven R; Head E; LeVine H; Spires-Jones TL; Catalano SM
    PLoS One; 2014; 9(11):e111899. PubMed ID: 25390692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ.
    O'Nuallain B; Klyubin I; Mc Donald JM; Foster JS; Welzel A; Barry A; Dykoski RK; Cleary JP; Gebbink MF; Rowan MJ; Walsh DM
    J Neurochem; 2011 Oct; 119(1):189-201. PubMed ID: 21781116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The conformational epitope for a new Aβ42 protofibril-selective antibody partially overlaps with the peptide N-terminal region.
    Colvin BA; Rogers VA; Kulas JA; Ridgway EA; Amtashar FS; Combs CK; Nichols MR
    J Neurochem; 2017 Dec; 143(6):736-749. PubMed ID: 28881033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease.
    Murakami K
    Biosci Biotechnol Biochem; 2014; 78(8):1293-305. PubMed ID: 25130729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening.
    Chang L; Bakhos L; Wang Z; Venton DL; Klein WL
    J Mol Neurosci; 2003; 20(3):305-13. PubMed ID: 14501013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-β in a fraction of amyloid-β deposits in Alzheimer's disease without cross-reactivity with other protein aggregates.
    Venkataramani V; Wirths O; Budka H; Härtig W; Kovacs GG; Bayer TA
    J Alzheimers Dis; 2012; 29(2):361-71. PubMed ID: 22232007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking the Interaction between EphB2 and ADDLs by a Small Peptide Rescues Impaired Synaptic Plasticity and Memory Deficits in a Mouse Model of Alzheimer's Disease.
    Shi XD; Sun K; Hu R; Liu XY; Hu QM; Sun XY; Yao B; Sun N; Hao JR; Wei P; Han Y; Gao C
    J Neurosci; 2016 Nov; 36(47):11959-11973. PubMed ID: 27881781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease.
    Barghorn S; Nimmrich V; Striebinger A; Krantz C; Keller P; Janson B; Bahr M; Schmidt M; Bitner RS; Harlan J; Barlow E; Ebert U; Hillen H
    J Neurochem; 2005 Nov; 95(3):834-47. PubMed ID: 16135089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.
    Lambert MP; Viola KL; Chromy BA; Chang L; Morgan TE; Yu J; Venton DL; Krafft GA; Finch CE; Klein WL
    J Neurochem; 2001 Nov; 79(3):595-605. PubMed ID: 11701763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
    Meli G; Visintin M; Cannistraci I; Cattaneo A
    J Mol Biol; 2009 Apr; 387(3):584-606. PubMed ID: 19361429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide.
    Moretto N; Bolchi A; Rivetti C; Imbimbo BP; Villetti G; Pietrini V; Polonelli L; Del Signore S; Smith KM; Ferrante RJ; Ottonello S
    J Biol Chem; 2007 Apr; 282(15):11436-45. PubMed ID: 17267402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and Partial Characterization of Rabbit Monoclonal Antibody to Pyroglutamate Amyloid-β3-42 (pE3-Aβ).
    Mehta PD; Patrick BA; Barshatzky M; Mehta SP; Frackowiak J; Mazur-Kolecka B; Wegiel J; Wisniewski T; Miller DL
    J Alzheimers Dis; 2018; 62(4):1635-1649. PubMed ID: 29504532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
    Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
    Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
    Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
    PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.